These findings, therefore, suggest that STAT3/CDK2/4/6 participates in the immune invasion of the above-mentioned cancers, thus providing a new window for monitoring the tumor immune microenvironment and may serve as a potential prognostic biomarker of an immune response in those cancer [57]. The gene discussed is CDK2; the disease is cancer.